Articles related to CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Leukemia progression depends on where cells are affected in the maturation process, determining treatment urgency and functional capacity of abnormal blood cells.

Despite poor prognosis at treatment initiation, extended follow-up reveals sustained remissions suggesting curative potential in heavily pretreated CLL patients receiving CD19-directed cellular immunotherapy.

The emergence of novel agents including BTK degraders, next-generation BCL2 inhibitors, and optimized combination approaches is reshaping the CLL treatment landscape, with multiple trials demonstrating high uMRD rates, improved progression-free survival, and manageable toxicity profiles across different patient populations.

Fixed-duration venetoclax-based therapy demonstrates sustained efficacy in CLL, with 65.2% of first-line patients remaining treatment-free five years after completion.

Five-year survival rates for chronic lymphocytic leukemia show promising outcomes even in elderly patients, with 77% survival in those 75 and older.

Lisocabtagene maraleucel offers a new treatment option for patients with CLL who have progressed on both BTK and BCL2 inhibitors, addressing an important unmet need in this patient population.